U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07608666) titled 'Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets' on May 20.

Brief Summary: Primary objective: To evaluate the effect of rabeprazole on the pharmacokinetics of TQ05105 tablets.

Secondary objective: To assess the safety and tolerability of single oral administration of TQ05105 tablets alone and in combination with rabeprazole in healthy study participants.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Myelofibrosis

Intervention: DRUG: TQ05105 tablets

TQ05105 tablets are Janus kinase (JAK) inhibitors.

DRUG: Rabeprazole sodium enteric-coate...